Stock Ratings / Health Care / INVA / insiders

ETON (58) GPCR (27) PAHC (56) TYRA (31) ⌘ Pro Terminal →

Innoviva Inc. (INVA) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$21.31 +0.90% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $21.30

Innoviva Inc. (INVA) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 67/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.6% avg 90D alpha vs SPY) →

ROARABLE C+ • HOLD / WATCH Cap $1.54B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INVA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is INVA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Innoviva Inc. (NASDAQ: INVA) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $21.31 (+0.90% 1D, market cap $1.54B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, INVA ranks #110 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does INVA compare to ETON and GPCR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), INVA carries a Roarable C+ (67/100 RQD), trailing P/E of N/A, gross margin of 74.8%, and ROIC of 14.7%. By comparison, ETON (Eton Pharmaceuticals Inc.) holds a D+ grade (58/100 RQD, P/E N/A, ROIC -0.9%, cap $1.53B) and GPCR (Structure Therapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -19.5%, cap $1.56B). Among the 5-stock peer group, PAHC leads on earnings multiple (32.7x) while INVA leads on capital efficiency (14.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INVA?

▼

Per INVA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001080014), Innoviva Inc. generated $411.3M in revenue (+14.7% YoY), $0 in net income, and $195.8M in free cash flow against $1.64B in total assets and $257.7M in total debt. Key quantitative strengths: Strong cash generator (75% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $21.30 (-0.03%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 15/20 (B) • 47.6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 67/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.6% avg 90D alpha vs SPY • 56.4% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk C+

Each axis scored 0–20

12M PRICE TARGET CONE+4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INVA)Realized 20D OHLCV Swing Band: ±4.6%

Deterministic 5-Pillar Attribution (67/100 Composite)

🔍 WHY INVA SCORES 67/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+15/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 47.6% FCF Margin ($195.8M FCF) & 74.8% Gross Margin

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (22% of score)

SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning10/20 pts (-10 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-10 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B+$21.45-1.7% Next Q

Q2 (-2Q)

Grade B$21.08-0.1% Next Q

Q3 (-1Q)

Grade B$21.05+1.2% Next Q

Current

Grade C+$21.31+1.6% Hist 90D α

Trajectory: B+ (75) → C+ (67)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the INVA Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 67/100 (C+) score, INVA faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 72.3% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($20.99) or 200D SMA ($21.89) invalidates the momentum regime and cuts Target Base ($22.17) toward Bear Floor ($17.29).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INVA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “INVA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 67%NO 33%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

INVA Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (INVA)

No recent open-market Form 4 cluster sales or emergency dumps flagged on INVA. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (INVA Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

INVA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -7.31%📐 HORIZONTAL RANGE

2026-11-02O $21.12H $21.31L $21.12C $21.31VOL 626.9K

RES: $21.78SUP: $20.26SMA50: $20.99SMA200: $21.89

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INVA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INVA Butterfly Map → + Track INVA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-2.2%/yr Implied 5Y Growth

vs. +14.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on INVA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INVA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for INVA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INVA)

Health Care Rank #110 of 1016 ⚔️ ETON vs INVA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INVA vs. ETON, GPCR, PAHC, TYRA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Innoviva Inc. (INVA) ranks #110 by composite RQD confidence (67/100, grade C+) and #302 by equity capitalization ($1.54B). Within this direct 5-issuer industry benchmark cohort, PAHC leads on earnings valuation at 32.7x trailing P/E, while INVA leads on capital efficiency and profitability with 14.7% ROIC and 74.8% gross margin. INVA currently leads its immediate peer cohort in composite quantitative strength at 67/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
INVA ACTIVE Innoviva Inc.	C+	67/100	—	74.8%	14.7%	+0.90%	$1.54B	Benchmark Subject
ETON Eton Pharmaceuticals Inc.	D+	58/100	—	53.5%	-0.9%	+3.61%	$1.53B	/eton-vs-inva →
GPCR Structure Therapeutics Inc.	E	27/100	—	—	-19.5%	+2.14%	$1.56B	/gpcr-vs-inva →
PAHC Phibro Animal Health Corporation (Class A)	D+	56/100	32.7x	30.9%	9.9%	+2.59%	$1.58B	/pahc-vs-inva →
TYRA Tyra Biosciences Inc.	E	31/100	—	—	-35.0%	-1.24%	$1.48B	/tyra-vs-inva →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001080014

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Innoviva Inc. (INVA) reported GAAP revenue of $411.3M (+14.7% vs. FY2024 revenue of $358.7M , and +32.5% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of $196.9M, and free cash flow of $195.8M (+3.9% YoY). On the balance sheet, INVA closed FY2025 with $1.64B in total assets against $257.7M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$411.3M	$0	$196.9M	$195.8M	$1.64B	$257.7M
FY2024 (FY)	2024-12-31	$358.7M	$0	$188.7M	$188.4M	$1.30B	$256.3M
FY2023 (FY)	2023-12-31	$310.5M	$0	$141.1M	$141.1M	—	—

3. INVA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INVA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does INVA compare to ETON and GPCR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for INVA?

Where is INVA trading relative to its 50-day, 200-day, and 52-week technical levels?

INVA last traded at $21.31 (+0.90% on volume of 626,944 shares), positioning the stock +1.52% above its 50-day simple moving average ($20.99) and -2.65% below its 200-day simple moving average ($21.89). Across its 52-week range of $17.77 to $25.15, INVA sits at the 48.0% percentile with a 14-day RSI of 54.7 (NEUTRAL RANGE) and an implied next-earnings move of ±4.6% ($20.33 to $22.29).

INVA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are INVA insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies INVA leadership and institutional positioning as: HEAVY INSIDER & 13F ACCUMULATION.

Direct Sub-Reports: INVA RQD Cockpit INVA 12M Forecast INVA Earnings & Move INVA Dividends & DRIP INVA Insiders & 13F INVA Whale Options INVA Profit Sankey INVA News & Why